ICC Tribunal Rules in Favor of AOP Health in BESREMi® Arbitration Case
ICC Tribunal Rules in Favor of AOP Health in BESREMi® Arbitration Case An International Chamber of Commerce (ICC) tribunal has issued a partial final award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in an ongoing legal dispute with…
Pneuma Respiratory Enhances Inhaled Therapies for Better Respiratory Health
Pneuma Respiratory Enhances Inhaled Therapies for Better Respiratory Health Pneuma Respiratory, a leading med-tech and pharmaceutical company, is pioneering innovative solutions in inhaled respiratory therapeutics aimed at transforming respiratory care. With a focus on treating smoking-related lung conditions, Pneuma is…
Cellistic Unveils Allo Chassis™: Immune-Cloaked iPSC Cell Lines for Cost-Effective Cell Therapy
Cellistic Unveils Allo Chassis™: Immune-Cloaked iPSC Cell Lines for Cost-Effective Cell Therapy Cellistic, a leader in iPSC-based off-the-shelf cell therapy development and manufacturing services, has introduced its innovative Allo Chassis™—a new line of immune-cloaked iPSC cell lines derived from CD34+…
InnoCare Announces Phase III Study Approval of ICP-248 and Orelabrutinib for CLL/SLL in China
InnoCare Announces Phase III Study Approval of ICP-248 and Orelabrutinib for CLL/SLL in China InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focused on developing therapies for cancer and autoimmune diseases, has announced that the Center for Drug…
BioIntelliSense Teams Up with Hicuity Health for Scalable Continuous Patient Monitoring
BioIntelliSense Teams Up with Hicuity Health for Scalable Continuous Patient Monitoring BioIntelliSense, a leader in continuous health monitoring and clinical intelligence, has announced a strategic partnership with Hicuity Health, a leading provider of tech-enabled virtual care services. This collaboration aims…
Abridge Secures $250M Series D, Unveils New Contextual Reasoning Engine for Healthcare
Abridge Secures $250M Series D, Unveils New Contextual Reasoning Engine for Healthcare Abridge, a leader in generative AI for clinical conversations, has secured a $250 million Series D funding round. This milestone comes as the company surpasses 100 deployments across…
FDA Approves GSK’s PENMENVY 5-in-1 Meningococcal Vaccine
FDA Approves GSK’s PENMENVY 5-in-1 Meningococcal Vaccine GSK plc (LSE/NYSE: GSK) has announced that the U.S. Food and Drug Administration (FDA) has approved its PENMENVY vaccine (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged…
LimmaTech Begins Phase 1 Trial of Staphylococcus aureus Vaccine LBT-SA7
LimmaTech Begins Phase 1 Trial of Staphylococcus aureus Vaccine LBT-SA7 LimmaTech Biologics AG, a clinical-stage biotech company focused on developing vaccines for life-threatening diseases, announced the vaccination of the first participants in a Phase 1 controlled study of its multivalent…
UK’s EDX Medical Develops New ‘Super Test’ for Prostate Cancer
UK’s EDX Medical Develops New ‘Super Test’ for Prostate Cancer Scientists in Cambridge have created a groundbreaking new ‘super test’ for prostate cancer, aiming to transform the way the disease is screened and diagnosed. This innovative test is designed to…
Innate Pharma’s Lacutamab Receives FDA Breakthrough Therapy Designation for Sézary Syndrome
Innate Pharma’s Lacutamab Receives FDA Breakthrough Therapy Designation for Sézary Syndrome Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an innovative anti-KIR3DL2…
Two Dedicated Team Members Awarded the Graeme Rabbits Scholarship
Two Dedicated Team Members Awarded the Graeme Rabbits Scholarship Two deserving individuals are one step closer to achieving their career aspirations in behavioural neuroscience and social work, thanks to receiving $10,000 each toward their tertiary education. The Graeme Rabbits Scholarship,…
Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety and Durable Response in Psoriasis
Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety and Durable Response in Psoriasis Bristol Myers Squibb (NYSE:BMY) has announced new five-year data from the POETYK PSO long-term extension (LTE) trial, evaluating Sotyktu (deucravacitinib) in adult patients with moderate-to-severe plaque psoriasis. The…